CN1911238A - 用于皮肤的组合物及其使用方法 - Google Patents
用于皮肤的组合物及其使用方法 Download PDFInfo
- Publication number
- CN1911238A CN1911238A CNA2005100897554A CN200510089755A CN1911238A CN 1911238 A CN1911238 A CN 1911238A CN A2005100897554 A CNA2005100897554 A CN A2005100897554A CN 200510089755 A CN200510089755 A CN 200510089755A CN 1911238 A CN1911238 A CN 1911238A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- skin
- acne
- compositions
- carotene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 70
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 62
- 206010000496 acne Diseases 0.000 claims abstract description 58
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 39
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 35
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 35
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 35
- 229940046009 vitamin E Drugs 0.000 claims abstract description 35
- 239000011709 vitamin E Substances 0.000 claims abstract description 35
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 31
- 239000011718 vitamin C Substances 0.000 claims abstract description 31
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 31
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 30
- 235000005473 carotenes Nutrition 0.000 claims abstract description 30
- 150000001746 carotenes Chemical class 0.000 claims abstract description 30
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims abstract description 30
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 30
- 239000011720 vitamin B Substances 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 235000013599 spices Nutrition 0.000 claims description 25
- 239000004094 surface-active agent Substances 0.000 claims description 16
- 239000002562 thickening agent Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 229940088594 vitamin Drugs 0.000 claims description 11
- 229930003231 vitamin Natural products 0.000 claims description 11
- 235000013343 vitamin Nutrition 0.000 claims description 11
- 239000011782 vitamin Substances 0.000 claims description 11
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- 229930003270 Vitamin B Natural products 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 29
- 229940046001 vitamin b complex Drugs 0.000 abstract description 21
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 52
- 239000012153 distilled water Substances 0.000 description 20
- 210000002374 sebum Anatomy 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 12
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 12
- 239000001768 carboxy methyl cellulose Substances 0.000 description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 11
- 239000004141 Sodium laurylsulphate Substances 0.000 description 11
- 235000010489 acacia gum Nutrition 0.000 description 11
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 11
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 11
- 229960001727 tretinoin Drugs 0.000 description 11
- 238000004821 distillation Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 229930002330 retinoic acid Natural products 0.000 description 10
- 239000002689 soil Substances 0.000 description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 9
- -1 dimethyl sulfoxine Chemical compound 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 210000004209 hair Anatomy 0.000 description 8
- 206010037888 Rash pustular Diseases 0.000 description 7
- 210000001061 forehead Anatomy 0.000 description 7
- 239000003961 penetration enhancing agent Substances 0.000 description 7
- 208000029561 pustule Diseases 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 210000001732 sebaceous gland Anatomy 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 208000031513 cyst Diseases 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 5
- 231100000241 scar Toxicity 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 206010011732 Cyst Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229920000832 Cutin Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 206010039792 Seborrhoea Diseases 0.000 description 3
- 206010048222 Xerosis Diseases 0.000 description 3
- 238000001266 bandaging Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000004299 exfoliation Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000013316 zoning Methods 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- 101100049623 Mus musculus Wasf1 gene Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- 229960000878 docusate sodium Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CRKGMGQUHDNAPB-UHFFFAOYSA-N Sulconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CSC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 CRKGMGQUHDNAPB-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940100539 dibutyl adipate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- UIUXUFNYAYAMOE-UHFFFAOYSA-N methylsilane Chemical compound [SiH3]C UIUXUFNYAYAMOE-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229960004718 sulconazole nitrate Drugs 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940063678 vibramycin Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000021470 vitamin B5 (pantothenic acid) Nutrition 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明揭示一种局部使用的组合物,其主要由1%-45%w/w维生素C、1%-5%w/wB族维生素、0.1%-3%w/w胡萝卜素、2%-90%w/w维生素E所组成,具有保养皮肤、保湿、治疗痤疮、粉刺、青春痘以及抗氧化作用。
Description
技术领域
本发明揭示一种局部使用的组合物,用于保养皮肤、保湿、治疗痤疮、粉刺、青春痘以及抗氧化的作用,是不含维生素A酸的组合物。
背景技术
人体皮肤的构造包括有表皮、真皮、皮下脂肪组织、皮脂腺、汗腺、毛发及指甲,表皮下面厚的一层,称为真皮,毛发被周围的毛囊所包围,其侧面附有皮脂线。皮脂线会分泌皮脂,皮脂就会经由毛发和毛囊,渗透到皮肤表面,然后变成脂肪薄膜,附着在皮肤表面,有保护皮肤的功能。皮脂腺的多寡影响皮肤的类型,通常区分为油性皮肤、干性皮肤与混合性皮肤。
痤疮(acne)通常认为是粉刺、青春痘,属于一种毛囊、皮脂腺的慢性炎症。然而青春痘通常出现在额头、鼻翼四周、两颊,甚至背部、前胸、大腿等全身有毛囊的地方,可随其呈现症状区分为粉刺型、发炎红肿型及囊肿型。青春期男女当性腺开始成熟、睾丸及卵巢、肾上腺的雄性激素含量增高,因而刺激人体皮肤的皮脂腺,使其肥大,分泌大量的皮脂,而堆积皮脂腺、毛囊,经细菌作用而发炎。通常先形成黑头粉刺或白头粉刺,粉刺再受到细菌感染形成丘疹、脓疱、结节、囊肿等症候,就是青春痘。另外当男性荷尔蒙分泌过多,可能在面部T字部位及眼皮下面的皮肤,出现红、痒、热、烫、脱皮的现象,有时候甚至还会明显出现微血管;此称为脂漏性皮肤炎。
通常外用剂期待能够产生皮肤的清洁、杀菌作用,防止皮肤水份的蒸发,增进保湿作用等效果。例如美国专利第3,574,854号记载关于含氯化钠成分可以柔软肌肤的乳霜,德国专利公开第3,327,840号说明书揭示含矿物质盐类使肌肤卫生洁净的申请案。美国专利第3,859,436号则记载混合葡萄糖可使肌肤润滑的糖类,美国专利3,777,597号公报记载刮胡须用葡萄糖水溶液。
氯化钠虽然可成为维持体液渗透压的主体,尤其0.9%溶液被称为生理食盐水,但高浓度的氯化钠溶液,无法自皮肤吸收,反而刺激皮肤粘膜引起脱水作用。因此添加氯化钠的外用剂虽可刺激皮肤或杀菌,但很难改善防止皮肤水分蒸发的促进保湿作用等。
葡萄糖虽然可提高糖分原质,亢进全身细胞机能,增进生物体代谢机能的营养剂,亦具有解毒作用。但是除非做为口服补给,经由静脉注射或肌肉注射而提供补给。直接敷布于皮肤的外用剂中即使添加葡萄糖,亦难以期待此等葡萄糖呈现特有效果。
各种局部使用的药学活性剂,添加经皮吸收增进剂,通常采用己二酸二丁酯及己二酸二丁酯与豆蔻酸异丙酯的混合物。豆蔻酸异丙酯已知为局部配方的渗透促进剂。但是,申请人未在任何参考数据中得知DBA及IPM组合物的皮肤渗透促进的协合效果。
各种治疗剂及化妆剂用于处理数种皮肤症状,例如,异位性皮肤炎中搔痒及红斑所用的氢化可体松,皮肤霉菌感染用的硝酸沙卡那唑(sulconazolenitrate),光老化用的揣汀挪(tretinoin),及牛皮癣与皮肤癌用的5-氟尿嘧啶。在皮肤病治疗中通常添加渗透促进剂,例如二甲亚砜(DMSO),二甲基甲酰胺,甲基癸基亚砜(美国专利(US Patent)第3,527,864号),二甲基乙酰胺(美国专利第3,472,931号),及N-烷基-2-
咯烷酮(美国专利第3,696,516号)。但是,上述渗透促进剂足以产生一些缺点;例如,二甲亚砜有异味及体臭,在皮肤造成灼伤及红斑,减低水晶体皮肤的透明性,甚至于造成动物的组织坏死(Martindale,The Extra Pharmacopoeia,pages 1461-1463,Twenty-Seventh Edition,1977)。二甲基甲酰胺及二甲基乙酰胺亦在皮肤造成烧灼感及红斑。
Trebosc等人的美国专利第5,030,451号叙述含改良咖啡因衍生物作为活性剂的化妆组合物,称该公开的配方具有“良好及长效的分解脂肪的性质,因而证明在瘦身计划及治疗皮脂粒上非常有效”。Mausner美国专利第5,215,759号使用甲基硅烷醇茶碱乙酸盐海藻酸盐(methylsilanoltheophyllinacetate alginate)及甲基硅烷醇甘露糖醛酸盐(methylsilanolmannuronate)供作去脂肪(anti-cellulite)的成分。
局部施用视黄质(retinoid)如Kligman的美国专利第5,051,449号,能有限度地改善脂肪粒。Kligman称包括皮肤增厚,新血管增加,及使用捏挟测试(第6栏,第50-61行)可观察到中度至明显的改善。
美国专利申请第20020099094号揭示以胺基左旋醣酸光力疗法(aminolevulinic acid-photodynamic therapy)“Topical aminolevulinicacid-photodynamic therapy for the treatment of acne vulgaris”。美国专利申请第20020061855号揭示使用水、乙二醇(glycol)的治疗痤疮组合物,美国专利申请第20010056071号揭示使用resveratrol(3,4’,5-trihydroxy-trans-stilbene)、退黑激素(melatonin)、维生素(vitamins)D、E、A的治疗痤疮组合物。美国专利第5,710,177号揭示使用生物素(biotin),生物素酯类(biotin esters)、羟基羧酸(hydroxycarboxylic acids)、抗氧化剂(antioxidant),而美国专利第4,938,960号揭示使用B族维生素维生素、维生素E、维生素C、磷脂质(phospholipid)保护皮肤。
由上述数据可知,虽然有些专利宣称具有治疗痤疮、或是去脂肪、处理数种皮肤症状的治疗作用,但是其均与本发明不含维生素A酸的局部使用组合物不同。
发明内容
本发明主要目的揭示局部使用不含维生素A酸的组合物,可呈现皮肤保养、保湿,以及治疗痤疮、粉刺、青春痘及抗氧化作用的组合物。
本发明揭示一种局部使用组合物,不含维生素A酸可用于保养皮肤、保湿、治疗痤疮、粉刺、青春痘的组合物。虽然Shapiro SS与Saliou C.在2001年Nutrition第17卷第10期第839页至第44页说明以维生素A、维生素D及其衍生物搭配维生素C、维生素E、辅酶Q的类抗氧化物可改善皮肤,治疗痤疮。但是其未提供整个可以实施的处方。因为上述的维生素类是产生人体生理活性的重要物质。
维生素A酸(Vitamin A Acid)又称为Tretinoin,Retnoids,其结构上属于维生素A的一种衍生物。A酸主要作用为去角质的药品,因为它会将表皮的角质层最上层的角质去除,可以改善毛孔的阻塞,也可以改善皮肤皱纹、脸部周边循环血流、减少色素斑痕和阻断皮肤角化的作用,亦可促进上皮细胞换新和促进脱落,抑制角质合成,防止面疱的形成。但是多数维生素A酸制品存在着使肌肤产生光敏感,以及过度使用产生皮肤干燥、红肿、发热、发痒、皮肤炎等副作用。
B族维生素,并非单一种而是十数种合在一起的维生素,包括维生素B1(thiamin)、维生素B2(riboflavin)、烟碱酸(Niacin)、维生素B5(pantothenic acid)、维生素B6(pyridoxal)、叶酸(folic acid)、维生素B12(cobalamin)、生物素(biotin)。其主要功能为辅酶的成份,负责葡萄糖氧化,脂肪和蛋白质释放能量的辅酶。维持神经系统的正常功能,为生长、细胞再生、血球生成与合成核蛋白和髓鞘质(myelin)所必需,并能活化叶酸辅助酵素而促进红血球生成。
维生素E被认为是一个抗氧化剂,能抑制血小板的凝集,防止红血球细胞膜氧化以免其遭破坏而造成贫血,在组织内维持细胞膜完整以及促进亚麻油酸的正常功能。保护肌肉和神经组织的构造和功能,以增加末端血管的血流量,可有效改善情形。虽然,维生素E具备上述的活性,但是目前上市的品牌中如维生素E搭配芦荟哇绿(Wal Green)的商品,含维生素E的罗活益(L’oreal Furtur E),或是将松(Jasom Natural Cosmetics),并无记载具有保养皮肤,或是治疗痤疮、粉刺、青春痘,以及抗氧化的功能。且由本发明的局部使用组合物的活性实验,显示本发明组合物的主要成分所搭配的比例,具备良好功效。因此必须强调本发明的局部使用组合物,虽然以维生素C、B族维生素、胡萝卜素、维生素E与香料、增稠剂、表面活性剂所组成,然而并非本领域普通技术人员所能推定的。
本发明的局部使用的组合物,主要利用维生素C、B族维生素、胡萝卜素、维生素E与辅料(包括香料、增稠剂、表面活性剂)所组成。基于该组合物中某些成分均为人体必须的维生素,且主成分中不含维生素A酸,即使长期使用亦无过量或骨质疏松的疑虑。维生素在体内虽然需要量少,其涉及的功能却极重要,但是人体无法自行合成,因此必需依靠外界的提供。维生素C在人体中具有防止过氧化脂质的产生、促进胶原质的形成、作为许多酵素的辅酶、延缓细胞老化的功能,并且能促进血液的循环、可将黑色素逐渐还原。因此被认为可以帮助皮肤再生,具有抑制黑色素的产生,以及增强免疫力。
虽然美国专利第5,834,445号叙述含胡萝卜素与维生素E可到达粘膜的兰格汉氏(langerhans)细胞因而增进局部免疫作用。然而由于胡萝卜素含有颇重的色泽,且属于脂溶性因而在一些乳霜、乳剂、面霜的皮肤或是化妆品制剂中,存在着技术性问题。
本发明的局部使用的组合物由占组合物总重量的1~45%维生素C、1~5%B族维生素、0.1~5%胡萝卜素、2~90%维生素E以及余量的辅料和水组成。其中所述辅料可为占组合物总重量的0.1~2%香料、1~5%增稠剂、1~8%表面活性剂。
优选的处方可为维生素C为4~15%、B族维生素为1~5%、胡萝卜素为0.1~3%W/W、维生素E为15~65%。
本发明揭示一种不含维生素A酸的组合物,其由上述组成而呈现保养皮肤、保湿,以及痤疮、粉刺、青春痘的治疗效果。由于本发明是将维生素C、B族维生素、胡萝卜素、维生素E与香料、增稠剂、表面活性剂所组成的完整处方,与口服习知单一维生素类化合物所呈现的活性不同。且本发明直接局部涂敷于痤疮、粉刺、青春痘的患处,具有抗氧化与消除痤疮、粉刺、青春痘的效果,局部使用于皮肤、颜面等肢体的局部位置,以达到保养皮肤、保湿的效果。
本发明的组合物必要时添加各种赋形剂、载体、或稀释剂,可供直接涂敷患处的软膏剂型、乳剂、洗剂或是贴剂。其中,表面活性剂可选用十二烷基硫酸钠(sodium laury sulfate)、多库酯钠(docusate sodium)、吐温80(tween80)、吐温60(tween 60)、吐温20(tween 20)。增稠剂可选用羧甲基纤维素钠(sodium carboxymethyl cellulose,Na CMC)、羟丙基纤维素(hydroxy propylcellulose)、羟丙基甲基纤维素(hydroxy propyl methyl cellulose)、阿拉伯胶(acacia)、聚维酮(povidone)。该等剂型依已知的制剂方法于添加淀粉、羧酸甲基纤维素钠等类黏合剂,或以磷酸盐类缓冲液调整酸碱度使其pH值达适当程度。该等剂型亦可依已知的制剂方法或添加渗透促进剂,选用甘草等天然植物的萃取物。
附图说明
图1 Lo-107处方使用于脸部前额部位的皮肤保湿效果
图2 Lo-107处方使用于脸颊部位的皮肤保湿效果
图3 Lo-108处方使用于脸部前额部位的皮肤保湿效果
图4 Lo-108处方使用于脸颊部位的皮肤保湿效果
上述附图中,空白柱形代表对照组结果,斜线柱形代表实验组结果;“*”代表实验组与对照组之间的差异已达1%的显著水平;“I”形代表标准偏差的范围。
具体实施方式
在说明整个局部使用组合物的各种实施方式,及其所达成目的与功效的后,将对该局部使用的组合物的制备方法及活性实验说明进行描述。
实施例1
处方Lo-107
维生素E 25%
维生素C 20%
维生素B复合物 2%
胡萝卜素 0.1%
香料 2%
土温60 8%
羧甲基纤维素钠 1%
蒸馏水 41.9%
将上述原料维生素C、维生素B复合物与少量蒸馏水相溶。另外将胡萝卜素、维生素E、香料、表面活性剂土温60、增稠剂羧甲基纤维素钠相混合。而后将两溶液相混合并补足蒸馏水量41.9%w/w。
实施例2
处方Lo-108
维生素E 65%
维生素C 4%
维生素B复合物 1%
胡萝卜素 1%
香料 1%
土温60 6.5%
羧甲基纤维素钠 4%
蒸馏水 17.5%
将上述原料维生素C、维生素B复合物与少量蒸馏水相溶。另外将胡萝卜素、维生素E、香料、表面活性剂土温60、增稠剂羧甲基纤维素钠相混合。而后将两溶液相混合并补足蒸馏水量17.5%w/w。
实施例3
处方Lo-109
维生素E 40%
维生素C 10%
维生素B复合物 3%
胡萝卜素 0.5%
香料 1%
十二烷基硫酸钠 8%
阿拉伯胶 5%
蒸馏水 32.5%
将上述原料维生素C、维生素B复合物与少量蒸馏水相溶。另外将胡萝卜素、维生素E、香料、表面活性剂十二烷基硫酸钠、增稠剂阿拉伯胶相混合。而后将两溶液相混合并补足蒸馏水量32.5%w/w。
实施例4
处方Lo-110
维生素E 20%
维生素C 30%
维生素B复合物 4%
胡萝卜素 4%
香料 2%
十二烷基硫酸钠 8%
阿拉伯胶 5%
蒸馏水 45%
将上述原料维生素C、维生素B复合物与少量蒸馏水相溶。另外将胡萝卜素、维生素E、香料、表面活性剂十二烷基硫酸钠、增稠剂阿拉伯胶相混合。而后将两溶液相混合并补足蒸馏水量45%w/w。
实施例5
处方Lo-122
维生素E 85%
维生素C 2%
维生素B复合物 1%
胡萝卜素 1%
香料 0.1%
十二烷基硫酸钠 3%
阿拉伯胶 2%
渗透促进剂 0.5%
蒸馏水 5.4%
将上述原料维生素C、维生素B复合物与少量蒸馏水相溶。另外将胡萝卜素、维生素E、香料、表面活性剂十二烷基硫酸钠、增稠剂阿拉伯胶相混合。而后将两溶液相混合并补足蒸馏水量5.4%w/w。
实施例六
处方Lo-130
维生素E 40%
维生素C 10%
维生素B复合物 3%
胡萝卜素 2%
香料 2%
十二烷基硫酸钠 10%
阿拉伯胶 5%
蒸馏水 28%
将上述原料维生素C、维生素B复合物、与少量蒸馏水相溶。另外将胡萝卜素、维生素E、香料、表面活性剂十二烷基硫酸钠、增稠剂阿拉伯胶相混合。而后将两溶液相混合并补足蒸馏水量28%w/w。
实施例七
处方Lo-18
维生素E 90%
维生素C 1%
维生素B复合物 1%
胡萝卜素 1%
香料 0.5%
土温60 3%
羧甲基纤维素钠 3%
蒸馏水 0.5%
将上述原料维生素C、维生素B复合物、与少量蒸馏水相溶。另外将胡萝卜素、维生素E、香料、表面活性剂土温60、增稠剂羧甲基纤维素钠相混合。而后将两溶液相混合并补足蒸馏水量0.5%w/w。
实施例八
处方Lo-27
维生素E 30%
维生素C 45%
维生素B复合物 1%
胡萝卜素 2%
香料 2%
土温60 8%
羧甲基纤维素钠 1%
渗透促进剂 0.1%
蒸馏水 10.9%
将上述原料维生素C、维生素B复合物、与少量蒸馏水相溶。另外将胡萝卜素、维生素E、香料、表面活性剂土温60、增稠剂羧甲基纤维素钠相混合。而后将两溶液相混合并补足蒸馏水量10.9%w/w。
实施例九
处方Lo-22
维生素E 80%
维生素C 4%
维生素B复合物 2%
胡萝卜素 3%
香料 0.1%
土温60 3%
阿拉伯胶 2%
蒸馏水 5.9%
将上述原料维生素C、维生素B复合物、与少量蒸馏水相溶。另外将胡萝卜素、维生素E、香料、表面活性剂土温60、增稠剂阿拉伯胶相混合。而后将两溶液相混合并补足蒸馏水量5.9%w/w。
实施例十
处方Lo-39
维生素E 30%
维生素C 10%
维生素B复合物 5%
胡萝卜素 2%
香料 2%
十二烷基硫酸钠 10%
羧甲基纤维素钠 5%
渗透促进剂 1.5%
蒸馏水 34.5%
将上述原料维生素C、维生素B复合物、与少量蒸馏水相溶。另外将胡萝卜素、维生素E、香料、表面活性剂十二烷基硫酸钠、增稠剂甲基纤维素钠相混合。而后将两溶液相混合并补足蒸馏水量34.5%w/w。
活性实验
试验一:痤疮病患使用Lo-108的疗效评估
材料及方法:本试验是采用开放式临床效用评估,于2001年2月至8月半年内选择门诊中的痤疮病患60名,男性(30名),女性(30名)年龄17才~42才平均25才。使用Lo-108局部敷面治疗共六个月,每天敷面最少3小时最长8小时(过夜)才除去。每两周回诊一次记痤疮数量及性质的改变,详细的使用方法如下:
1.患部先用洗面奶(皂)清洗干净后,待皮肤干燥再敷药。
2.敷药量2ml左右,再以纱布覆盖以免满溢四处。
3.敷药三小时以上再行洗净,不可擦拭任何保湿乳液(霜)。
4.若有脓包应先行挤去再行敷药。
若病患有脓包才配合口服抗生素如:四环霉素或呱迈信(Vibramycin)治疗一星期,其余时间禁用他种痤疮疗法,如维生素A酸(Vitamin AAcid)口服或外用,或荷尔蒙治疗法。结果的评估由医师及病患本人检定其粉刺数目、丘疹数目、脓包数目、红肿程度而订定严重等级及改善程度百分比。
结果
结果如表1所示,黑头及白头粉刺于8周的治疗后,数量有明显的减少由平均43.5个降至平均20.1个(p<0.01)的有意义减少,而且可以见到毛孔开口缩小的发红性丘疹更是有显著性的数量减少;由平均21.0个降至2.1个的有意义下降p<0.001。脓包及囊肿的红肿现象的消失,由平均数8.9及0.8降至没有半个的程度,仅仅残留部份红斑及凹陷的疤痕。其实红肿的减轻是在使用前四星期时,大部份的受测者已感到明显的改善,因而愿意续使用Lo-108来治疗他们的痤疮。在评估当中发现Lo-108具有消炎、降温、消红肿的能力外,似乎皮肤的过度角质化增生的现象亦有减少的情形,促使皮肤变得较为光滑。凹陷疤痕的改善。仅有伴有红肿者有些许改善,这可能是由消肿以后所得的印象。
过往所使用的去角质外用药或抗生素外用药常造成的皮肤干燥脱皮刺痛,甚或红肿等不良的感受,由于Lo-108兼具的保湿效应而未发生,但有部份受测则认为其颜色及味道较难忍受,但由于其效用而忍了下来。
综合以上的数据,可以认定Lo-108具有治疗痤疮的疗效,其作用可能需进一步做各类测试来探讨,例如它可能有去角质作用,减少皮脂分泌量、杀菌消炎并有增加角质含水量的作用而达成。
试验二:皮脂溢出抑制能力的对照评估
20个健康的自愿者参与此项临床试验,这些年岁在18至55才的间的被测试者的额头部位皮肤,分左右两边,一边涂抹Lo-108,一边不涂抹来加以对照。涂抹的方式是每天晚上涂抹约1ml~2ml的Lo-108三个小时后,清洗干净。这样总共涂了4星期。每星期回诊检测左、右两额各自的皮脂量。每次都在相同固定时间区间内接受检测。
皮脂溢出量的测试是用皮脂测量仪Sebometer 810 PC(Courage andKhazaka Ltd,Germany)测定皮表的油脂量,由于是测定左右皮脂量百分比差,因此许多干扰变量可以减至最低的程度。皮脂测量的原理利用器具前头的一块0.1mm厚,64mm2面积的不透明塑料物质,压在皮肤表面30秒后,因为吸收的皮脂使它变得透明度增加,而且可以和皮脂量成线性的增加,也就是说皮脂愈多透明度愈高的正相关。经由光度计的测量可经由公式转换成毫克/平方公分。
结果
本试验组及对照组由于是同一人额部,左右边皮肤的油脂测定,将气候中的温度,湿度变化,受测人的运动程度,流汗程度等干扰因素均加以除去。利用ANOVA(Analysis of variance)的统计方法得到数据,测试组的额部油脂有明显低于控制组。见图1的图标可以见到每周的平均差异似乎有愈来愈明显的倾向,但经由ANOVA统计法,如表2所示Lo-108的皮脂量数据表,皮脂量的增减在一周的使用已见到统计学上的明显差异(pr>F 0.0001)。但若以时间来算,如表3所示依时间长短所发生的油脂量差异,也就是使用愈久则仍有相似的结果,并没有真正的随时间而增加,发生没有意义的交互关系(pr>F 0.2854)。以上的结果显示,Lo-108可以有效去除或抑制油脂分泌达12小时以上,使皮脂腺的开口皮脂量(发生痤疮的主因的一)得到暂时性的舒缓。这种效用可以在短期内达成,虽无法证实使用愈多作用愈大,但若天天使用,却可以维持其抑制皮脂的效用长达四周以上。
试验三:灼伤及伤痕复原的动物实验
本实验所使用的八周大的雄性大白鼠(Wistar种),平日饲养于成功大学动物中心;南部唯一合乎国外要求(SPF)的动物培育单位。大白鼠饲养在具有空调且室温维持在25±1℃的动物室,所有大白鼠皆可自由进食及饮水。
灼伤实验
本项步骤主要参照Kistler等人的实验方法,并使用动物自身对照比较的观察。实验步骤叙述如下:每只大白鼠先以65mg/kg的pentobarbital麻醉,待其昏睡后,将背部分成四个固定区域,每个区域约4cm2;利用剃毛机将各区域内毛剃除干净。然后,分别用烧红的铁片(温度约在80-85℃左右)放置于背部的四个区域约10秒,造成大白鼠背部的烫伤。步骤结束后,取下铁片,并以双氧水(37%)作简单的消毒、清洁伤口。然后,再依划分区域分别投与不同的处理;除了对照用的区域不给药外,其余三区域分别给予Vitamin E,产品的基剂以及测试产品,以能均匀涂抹伤口面积为基准给与量。并于涂敷后,即刻使用紧密包扎法保护伤口,以确保伤口不受细菌感染。每天定时换药一两次并观察老鼠伤口变化,每日定期照相存证。连续七日后,将动物牺牲并取四个区域的组织作病理切片,委托新光医学中心的病理专家李进成博士恊助评估创面病理学的变化。
结果
由灼伤的恢复情形来看,在产品处理的部位,炎症的变化较为减弱。结果显示,对照部位的炎症与产品基剂处理部位没有多大差异。可是,产品处理的部位则较无炎症的变化。
伤口复原实验
本实验也是使用八周大雄性的大白鼠(Wistar种),依照上述的实验步骤,将麻醉的大白鼠背部分成四个固定区域,每个区域约4cm2,并使用剃毛机将各区域鼠毛剃除干净。然后,分别用手术刀在背部各区域割开约一公分长,深度可看肌肉层的伤痕。接着,以双氧水(37%)消毒并清洁伤口。同样地,再依划分区域分别投与不同的处理;除了对照区域不给药外,其余三组区域也是分别给予维生素E,产品的基剂以及测试产品,亦以能均匀涂抹伤口面积为基准给与量。并于涂敷后,即刻使用紧密包扎法保护伤口,以确保伤口不受细菌感染。每天定时换药一次并观察老鼠伤痕的复原惰形,每日定期照相存证。最后,依照复原到正常所需的日数来相互比较;日数愈少者,表示复原愈快。
本实验也是使用八周大雄性的大白鼠(Wistar种),依照上述的实验步骤,将麻醉的大白鼠背部分成四个固定区域,每个区域约4cm2,并使用剃毛机将各区域鼠毛剃除干净。然后,分别用手术刀在背部各区域割开约一公分长,深度可看肌肉层的伤痕。接着,以双氧水(37%)消毒并清洁伤口。同样地,再依划分区域分别投与不同的处理;除了对照区域不给药外,其余区域也是分别给予产品的基剂以及测试产品,亦以能均匀涂抹伤口面积为基准给与量。并于涂敷后,即刻使用紧密包扎法保护伤口,以确保伤口不受细菌感染。每天定时换药一次并观察老鼠伤痕的复原惰形,每日定期照相存证。最后,依照复原到正常所需的日数来相互比较;日数愈少者,表示复原愈快。
结果
由割伤的恢复情形来看,在产品处理的部位,复原的天数短;约7.13±1.27天(N=8)而巳。可是,对照部位的伤痕则要11.00±2.24天(N=8)左右;与产品基剂处理部位的10.13±1.62(N=8)没有多大差异(P>0.05)。
试验四:抑菌实验
本实验使用三种菌株分别为金葡萄球菌(Staphylococcus aureus,Methicillin Restant(ATCC 33591)、Staphylococcus aureus)、痤疮菌(Propionibacterium acnes(ATCC 6919)),经各别适用的培养基培养后,以0.03μl/ml、0.1μl/ml、0.3μl/ml、1μl/ml、3μl/ml、10μl/ml、30μl/ml、100μl/ml的Lo-110分析其抑菌浓度为100μl/ml。
试验五:皮肤保湿效果
筛选年龄20至40岁左右,过去未曾有皮肤对药物过敏反应,且三个月内没有皮肤疾病,两颊无伤痕的健康24名男女各半,随意区分为2群。受试者试验前及进行试验期间内,不可于实验部位涂抹任何物质,并减少两颊部位的流汗及太阳曝晒,签署试验同意书后进行下列实验。
每群12名男女,第一群涂抹Lo-107处方,第二群涂抹Lo-108处方。每名受试者左右两部分脸颊部位,量取约1ml制剂均匀涂抹于左半部(约15cm2)为实验组,右半部不涂抹为对照组。
受试者于下午4点到达试验地点,以中性洗液清洁脸部,15分钟后测量皮肤含水量基值(baseline)并涂抹产品。涂用时间30分钟,待时间到,皮表残余的制剂即以湿纸巾轻轻抹去,并以中性洗液清洁,15分钟后测量皮肤含水量(data)。皮肤含水量则以皮肤含水测定仪Corneometer CM825(Courage and Khazaka Ltd,Germany)测定,左右两额各测量2个位置。皮肤含水量以ANOVA(Analysis of variance)进行分析。
结果
结果发现,Lo-107、Lo-108两种处方使用于脸部前额部位,皮肤保湿效果偏弱,而使用于脸颊部位则有明显增加皮肤含水量的效果。
表1 Lo-108的疗效评估
| 敷药前 | 敷药8周后 | |
| 粉刺平均数(mean no.of comedones) | 43.5 | 20.1(p<0.01) |
| 丘疹平均数(mean no.of papules) | 21.0 | 2.1(p<0.001) |
| 脓包平均数(mean no.of pustules) | 8.9 | 0(p<0.0001) |
| 囊肿平均数(mean no.of cysts) | 0.8 | 0 |
表2 皮脂量的数据表
| 时间 | 敷药Lo-108组 | 对照组 |
| 0 | 88.15±13.02 | 93.85±12.82 |
| 1 | 82.80±12.40 | 94.00±13.52 |
| 2 | 88.00±9.53 | 112.55±12.88 |
| 3 | 81.75±11.24 | 118.8±12.66 |
| 4 | 61.15±8.36 | 99.95±10.38 |
注:以20个病人左脸颊敷药Lo-108为处理组,右脸颊擦基剂为对照组。
表3 油脂量差异
| 来源(Source) | 自由度(DF) | 变异度分析(Anova SS) | 均方(Mean Square) | F值 | Pr>F |
| 病人编号 | 19 | 229013.20 | 12053.33 | 6.88 | 0.0001 |
| 治疗的时间次数 | 4 | 11278.55 | 2819.64 | 1.61 | 0.1740 |
| 治疗 | 1 | 27518.58 | 27518.58 | 15.71 | 0.0001 |
| 治疗和时间的交互作用 | 4 | 8869.17 | 2217.29 | 1.27 | 0.2854 |
Claims (6)
1.一种局部使用的组合物,其由占组合物总重量的1~45%维生素C、1~5%B族维生素、0.1~3%胡萝卜素、2~90%维生素E以及余量的辅料和水组成。
2.如权利要求1所述的组合物,其中所述辅料为占组合物总重量的0.1~2%香料、1~5%增稠剂、1~8%表面活性剂。
3.如权利要求1-2任意一项所述的组合物,其中维生素C为4~15%、B族维生素为1~3%、胡萝卜素为0.1~2%W/W、维生素E为15~65%。
4.权利要求1-3中任意一项的组合物在制备治疗痤疮、粉刺、青春痘药物中的应用。
5.权利要求1-3中任意一项的组合物在保养皮肤中的应用。
6.权利要求1-3中任意一项的组合物在作为抗氧化剂中的应用。
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100897554A CN1911238A (zh) | 2005-08-08 | 2005-08-08 | 用于皮肤的组合物及其使用方法 |
| RU2006124239/15A RU2006124239A (ru) | 2005-08-08 | 2006-07-06 | Составы для применения на коже |
| CA002551690A CA2551690A1 (en) | 2005-08-08 | 2006-07-10 | Compositions for use with skin |
| EP06014265A EP1752132A3 (en) | 2005-08-08 | 2006-07-10 | Skin cosmetic compositions |
| ARP060103424A AR056018A1 (es) | 2005-08-08 | 2006-08-04 | Una composicion para usar en la piel |
| BRPI0603258-3A BRPI0603258A (pt) | 2005-08-08 | 2006-08-07 | composições para uso na pele |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100897554A CN1911238A (zh) | 2005-08-08 | 2005-08-08 | 用于皮肤的组合物及其使用方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1911238A true CN1911238A (zh) | 2007-02-14 |
Family
ID=37434245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005100897554A Pending CN1911238A (zh) | 2005-08-08 | 2005-08-08 | 用于皮肤的组合物及其使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1752132A3 (zh) |
| CN (1) | CN1911238A (zh) |
| AR (1) | AR056018A1 (zh) |
| BR (1) | BRPI0603258A (zh) |
| CA (1) | CA2551690A1 (zh) |
| RU (1) | RU2006124239A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101862274A (zh) * | 2010-05-28 | 2010-10-20 | 骆琦 | 一种含有叶酸的护肤品组合物及其制备方法 |
| CN102343085A (zh) * | 2010-08-02 | 2012-02-08 | 龚森淼 | 一种治疗皮肤创伤的水包油o/w乳液及其制造方法 |
| CN112263529A (zh) * | 2020-10-27 | 2021-01-26 | 圣菲之美(湖北)生物科技有限公司 | 一种抗衰老组合物及其制备方法和应用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR202020925A1 (tr) * | 2020-12-18 | 2022-06-21 | Eczacibasi Tueketim Ueruenleri Sanayi Ve Ticaret Anonim Sirketi | Ci̇lt yüzeyi̇nden su kaybinin azaltilmasi ve ci̇ldi̇n nem oraninin arttirilmasini sağlayan bi̇r solüsyon ve bi̇r ci̇lt bakim ürünü |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3504695A1 (de) * | 1985-02-12 | 1986-08-14 | Roshdy Dipl.-Chem. Dr. 5000 Köln Ismail | Haarwuchsmittel |
| LU87145A1 (fr) * | 1988-02-26 | 1989-09-20 | Oreal | Methode pour ameliorer l'aspect esthetique de la peau a l'aide de melanges polyvitaminiques |
| FR2694692B1 (fr) * | 1992-08-13 | 1994-10-28 | Thorel Jean Noel | Préparation cosmétique de nutrition de la peau. |
| US5962517A (en) * | 1997-01-31 | 1999-10-05 | Murad; Howard | Pharmaceutical compositions and methods for treating acne |
| JP2006525945A (ja) * | 2003-05-16 | 2006-11-16 | 美時化学製薬股▲ふん▼有限公司 | 皮膚を通して投薬される外用組成物 |
-
2005
- 2005-08-08 CN CNA2005100897554A patent/CN1911238A/zh active Pending
-
2006
- 2006-07-06 RU RU2006124239/15A patent/RU2006124239A/ru not_active Application Discontinuation
- 2006-07-10 EP EP06014265A patent/EP1752132A3/en not_active Withdrawn
- 2006-07-10 CA CA002551690A patent/CA2551690A1/en not_active Abandoned
- 2006-08-04 AR ARP060103424A patent/AR056018A1/es not_active Application Discontinuation
- 2006-08-07 BR BRPI0603258-3A patent/BRPI0603258A/pt not_active IP Right Cessation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101862274A (zh) * | 2010-05-28 | 2010-10-20 | 骆琦 | 一种含有叶酸的护肤品组合物及其制备方法 |
| CN102343085A (zh) * | 2010-08-02 | 2012-02-08 | 龚森淼 | 一种治疗皮肤创伤的水包油o/w乳液及其制造方法 |
| CN102343085B (zh) * | 2010-08-02 | 2014-08-27 | 龚森淼 | 一种治疗皮肤创伤的水包油o/w乳液及其制造方法 |
| CN112263529A (zh) * | 2020-10-27 | 2021-01-26 | 圣菲之美(湖北)生物科技有限公司 | 一种抗衰老组合物及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006124239A (ru) | 2008-01-20 |
| EP1752132A2 (en) | 2007-02-14 |
| BRPI0603258A (pt) | 2007-03-27 |
| AR056018A1 (es) | 2007-09-12 |
| EP1752132A3 (en) | 2010-01-13 |
| CA2551690A1 (en) | 2007-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Proksch et al. | Topical use of dexpanthenol: a 70th anniversary article | |
| Proksch et al. | The management of dry skin with topical emollients–recent perspectives: Behandlung der trockenen Haut mit topischen Emulsionen–neue Entwicklungen | |
| CN1202817A (zh) | 通过破坏隔离层对结构退化皮肤进行的护理 | |
| US20150044317A1 (en) | Topical Compositions for Reducing Visible Signs of Aging and Methods of Use Thereof | |
| JP6257518B2 (ja) | 皮膚剥脱のための組成物およびその使用 | |
| AU2012254214B2 (en) | A topical formulation for treatment of hyperkeratotic skin | |
| CN1547475A (zh) | 采用电子转移试剂的磷酸酯衍生物进行皮肤治疗 | |
| CN109431912A (zh) | 皮肤油脂平衡组合物及其应用 | |
| WO2024259730A1 (zh) | 一种控油祛痘沐浴露及其制备方法 | |
| CN1787806A (zh) | 皮肤病的局部治疗 | |
| Addor | Topical effects of SCA®(Cryptomphalus aspersa secretion) associated with regenerative and antioxidant ingredients on aged skin: evaluation by confocal and clinical microscopy | |
| CN115209887A (zh) | Ppar激动剂复合物及其使用方法 | |
| CN1250229C (zh) | 经皮给药的外用组合物 | |
| Wiśniewska et al. | Salicylic acid and its use in cosmetology | |
| JP2019065004A (ja) | 皮膚常在細菌叢改善剤及びこれを含有する化粧料又は皮膚外用剤 | |
| Lønne et al. | Composition characterization and clinical efficacy study of a salmon egg extract | |
| KR20190009364A (ko) | 피부 치료를 위한 제품의 신규 용도 | |
| CN1911238A (zh) | 用于皮肤的组合物及其使用方法 | |
| CN109431910A (zh) | 皮肤屏障修复组合物及其应用 | |
| Chilicka et al. | The effectiveness of alkaline water on oily and acne-prone skin: A case report | |
| JP2015086160A (ja) | 保湿剤、肌荒れ改善剤、角層水分量増加剤、血流改善剤及び肌のくすみ、くま又はつや改善剤 | |
| JP2024526110A (ja) | 皮膚バリアを改善するための組成物および方法 | |
| Van Leen et al. | MMRC (Alhydran®), an interesting treatment option for a disrupted skin barrier | |
| KR100502069B1 (ko) | 홍삼 조사포닌을 함유하는 여드름 개선용 부직포 팩 | |
| Ranosz et al. | Opinions of clients of cosmetology salons regarding the impact of wearing protective masks on the condition of the skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |